Claritron

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Claritron

Property Description
Active Ingredient Clarithromycin
Form Tablets, Extended-Release Tablets, Oral Suspension
Pharmacological Class Macrolide Antibiotic
Common Use Targeting Bacterial Infections
Origin Semi-Synthetic

What Type of Medication is Claritron?

Claritron, with the active substance Clarithromycin, is classified as a macrolide antibiotic, making it a recognized antimicrobial agent used to halt the proliferation of disease-causing bacteria. This medication is specifically targeted toward combating bacteria and is clinically recognized as ineffective against viral infections, such as influenza. Claritron is consistently positioned as a prescription-only medication, reinforcing the need for professional medical oversight.

Composition and Origin: Is Clarithromycin Semi-Synthetic?

The core chemical constituent, Clarithromycin (INN), is categorized as a semi-synthetic derivative, meaning it is manufactured by modifying the structure of the naturally occurring macrolide compound, Erythromycin. This structural change enhances the drug's properties, resulting in improved acid stability and better absorption when administered via the oral route. One differentiating factor is its formulation into specialized extended-release tablets, a feature that aims to simplify treatment adherence for certain patient groups by reducing dosing frequency compared to immediate-release forms.

General Forms and The Principle of Action

Claritron is provided in several dosage forms, including standard and extended-release tablets, as well as a liquid suspension typically used for pediatric patients. The general purpose of Claritron is to aid the body in resolving bacterial infections. This is achieved through its core mechanism of effect: it stops the bacteria from multiplying by blocking bacterial protein synthesis, which effectively minimizes the bacterial load and allows the patient’s immune system to clear the infection.

What side effects are possible with Claritron?

Claritron, like all medications, is associated with a range of possible side effects documented in regulatory sources, and carries specific long-term safety warnings.

General Adverse Reactions

Adverse reactions frequently involve the Gastrointestinal system, commonly including nausea, vomiting, diarrhea, and abdominal pain. Nervous system disorders such as taste disturbance (dysgeusia) are also common. Other affected system-organ classes include the Immune system (e.g., drug hypersensitivity, allergic reactions), Skin and Subcutaneous Tissue (e.g., rash, urticaria, and rare cases of Stevens-Johnson syndrome), and Hepatobiliary disorders (e.g., liver function damage).

Serious Safety Information

Regulatory bodies have issued a warning regarding a potential increased long-term risk of heart problems or death in patients with pre-existing heart disease, such as coronary heart disease. This risk was observed to manifest one year or longer after patients had completed a short, two-week course of treatment with Claritron. Due to this finding, the benefits of Claritron must be carefully weighed against the risks, particularly for patients with known heart conditions.

Population-Specific Notes

Adverse event reporting suggests variations across age groups: psychiatric events like nightmares are more commonly reported in adults, while younger patients have a closer association with gastrointestinal issues and drug hypersensitivity. Caution is advised when prescribing Claritron to elderly patients (geqslant65 years) due to a higher likelihood of concurrent severe kidney or heart rhythm problems and potential drug interactions.

Overdose and Emergency Response

Claritron overdose primarily presents as an exacerbation of common adverse reactions, typically involving significant gastrointestinal symptoms, such as severe abdominal pain, vomiting, nausea, and diarrhea. However, acute overdose carries the documented potential for severe and life-threatening systemic risks. These include the risk of cardiotoxicity, specifically QT interval prolongation and the serious irregular heart rhythm known as Torsades de pointes. Overdose may also lead to severe hepatic dysfunction and, in rare circumstances, hepatic failure.

Regulatory guidance mandates that patients seek immediate medical attention for any symptoms suggesting cardiac issues, and the drug must be discontinued immediately if signs of hepatitis or severe allergic reactions appear. The official management approach relies on general supportive measures and the prompt elimination of unabsorbed drug, as there is no specific antidote known for Clarithromycin overdose. Furthermore, regulatory information confirms that mechanical methods like hemodialysis or peritoneal dialysis are not expected to be effective in removing the drug from the system. It is also noted that elderly patients may have increased susceptibility to the cardiac effects involving the QT interval.

Therapeutic Uses of Claritron

What Claritron Treats: Main Uses and Benefits

Claritron is commonly used to help manage symptoms related to physical discomfort by targeting the bacteria linked to the symptoms. It is applied across domains where additional symptomatic support is needed to address infections in the respiratory system, skin, and gastrointestinal tract.

The medication is relevant in conditions characterized by periods of heightened symptoms such as conditions presenting with systemic or localized discomfort, including some forms of pneumonia, bronchitis, or middle ear infections. Claritron helps address symptom clusters that may become intense or disruptive, including fever, cough, sore throat, and localized pain.

It is also used in complex regimens for conditions involving inflammatory or irritative processes, such as managing gastrointestinal discomfort associated with the bacterium H. pylori, and in specialized contexts, may be relevant in managing challenging symptoms for patients with a known penicillin allergy. This treatment supports the patient during difficult episodes by easing distress and provides supportive relief when symptoms interfere with routine activities.


Common Use Context Claritron plays a role in managing symptoms like cough and fever associated with bacterial respiratory infections, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Claritron (Clarithromycin) is generally prescribed to adults and children without specific exclusionary conditions. However, governmental regulatory documents list several groups for whom use is contraindicated or not recommended.

Populations and Conditions for Restricted Use

Classification Who Must NOT Use Claritron (Contraindications)
Prior History Known allergy or hypersensitivity to clarithromycin or any macrolide antibiotic. History of cholestatic jaundice or liver dysfunction due to prior clarithromycin use.
Heart Conditions Patients with a documented history of QT prolongation (congenital or acquired), ventricular cardiac arrhythmia (including Torsades de Pointes), or uncorrected low potassium or magnesium levels.
Organ Function Patients with severe hepatic failure combined with renal impairment.
Drug-Specific Co-Use Concurrent use of certain medications, including cisapride, pimozide, ergot alkaloids (e.g., ergotamine), lovastatin, simvastatin, or lomitapide, due to the risk of severe or fatal toxicity. The co-administration of colchicine is also contraindicated in patients with existing kidney or liver impairment.

Age and Physiological Restrictions

  • Pediatric: Safety and efficacy have not been established for children younger than 6 months of age. Modified-release tablets are generally not for use in children under 12 years old.
  • Pregnancy/Lactation: Use during pregnancy is not recommended unless there is no appropriate alternative, and the clinical benefit outweighs the potential risk to the fetus, based on animal data showing harm. The medicine passes into breast milk; caution is advised for breastfeeding women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Claritron’s interaction profile is defined by its ability to inhibit key drug metabolizing enzymes, primarily CYP3A4, and drug transporters, leading to altered concentrations of many co-administered substances. This results in specific constraints and classifications as detailed in regulatory labeling.

Classification Examples of Interacting Medicines
Contraindicated Combinations Astemizole, Cisapride, Pimozide, Terfenadine, Lovastatin, Simvastatin, Ergotamine, Dihydroergotamine, Oral Midazolam
Use with Caution/Monitoring Digoxin, Warfarin, Triazolam, Alprazolam, Omeprazole

The co-administration of substances listed as contraindicated is strictly prohibited due to severe risks, such as rhabdomyolysis with specific statins and cardiac arrhythmias with certain antihistamines. For other interacting medicinal products, the regulatory basis requires increased monitoring or dose adjustments. For instance, Claritron increases the plasma concentration (AUC) of oral midazolam by seven-fold and boosts the level of the medicine Omeprazole increases Claritron's own minimum concentration ( Cmin) by mathbf27%.

Specific restrictions apply based on the formulation: the extended-release tablet form must be taken with food to ensure adequate absorption. Additionally, specific populations have noted risks, such as the interaction with Colchicine being contraindicated in patients with existing renal or hepatic impairment, as stated in official labeling.

Mechanism of Action

Claritron operates via two distinct mechanistic domains: one targeting the foreign organism and the other influencing the host's physiological response.

Targeting Foreign Organism's Protein Factory

Claritron acts as an inhibitor by selectively binding to the 50S ribosomal subunit within susceptible foreign organisms. This interaction blocks the movement of the ribosome along the messenger RNA, thereby preventing the elongation of the peptide chain. This molecular cascade leads to the inhibition of the organism's growth and multiplication. The resulting mechanistic consequence is a reduction in the population and replication rate of the foreign organism.

Modulating Host Immune Signaling

This secondary mechanistic domain involves Claritron's influence on host immune cells and the chemical messengers they produce. The drug acts as a modulator to adjust the signaling activity of inflammatory pathways, particularly by affecting the release of specific cytokines. This activity contributes to the physiological effect of modulating local inflammatory responses within the body.

Dosage and Administration Information

Official Administration Guidelines for Claritron

Claritron (Clarithromycin) must be administered strictly according to official prescribing information, which details the appropriate dosage, frequency, and duration of use. The medication is authorized for oral use (tablets, extended-release tablets, and suspension) and intravenous (IV) use in hospital settings when oral therapy is not possible.


Dosing and Administration Schedule

Formulation Adult Dosing (Typical Range) Frequency Duration (General Range)
Immediate-Release Tablets 250 mg to 500 mg Twice Daily ( q12h) 7 to 14 days
Extended-Release Tablets 1000 mg (as two 500 mg tabs) Once Daily ( q24h) 7 to 14 days

For pediatric patients (typically 6 months to 12 years), the dose is calculated based on body weight, commonly 7.5 mg/kg twice daily, using the oral suspension. Treatment for infections caused by Streptococcus pyogenes (e.g., pharyngitis) must be maintained for a minimum of 10 days.


Procedural Use Requirements

Intake Instructions:

  • Immediate-Release tablets and Oral Suspension may be taken with or without food. The suspension must be shaken well before each measured dose.
  • Extended-Release tablets must be taken with food and swallowed whole; they must not be crushed, broken, or chewed.

Dosage Adjustment: Official labels require a dose reduction by one-half (e.g., 250 mg once daily) for adult patients with severe renal impairment (creatinine clearance < 30 mL/min) to manage systemic exposure of the medicine. Intravenous therapy is generally administered over 60 minutes and is intended to be short-term before transitioning to the oral form.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Osteoarthritis (OA)

Primary research has explored whether the compound supports knee-joint function. Studies have also examined the potential for a reduction in pain reported by participants diagnosed with mild to moderate osteoarthritis (OA).

A multi-center study observed whether the compound was associated with a reduction in both pain scores and stiffness metrics over a 12-week period. Research has investigated the compound’s potential role in managing early-stage OA and its association with the frequency of non-steroidal anti-inflammatory drug (NSAID) use.

Studies evaluated whether the compound was associated with differences compared to a placebo in physical mobility metrics, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Research also examined whether the compound was associated with changes in joint-space width, which is a marker observed in disease progression.


Safety and Tolerability Profile

Research protocols involved evaluating safety outcomes in adult participants. Adverse event reporting was collected during the trials. The trials reported findings that included common adverse events such as mild gastrointestinal upset and headache.


Areas Requiring Further Study

  • The existing evidence base primarily consists of short-term studies (12 weeks or less). It is not yet clear whether the observed associations are maintained over a longer period, such as one year or more.
  • Studies have focused on mild to moderate OA; research has not yet widely explored the use of the compound in participants with severe OA or other joint disorders.

Key Studies & References

  1. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis (Rev. 1)

Frequently Asked Questions (FAQ)

Common questions about Claritron (FAQ)


Q: Can older people safely take Claritron?

A: Official prescribing information indicates that caution is necessary when this medicine is considered for patients aged 65 years and older. This is due to the higher likelihood of pre-existing severe kidney or heart rhythm problems and potential drug interactions in this age group.

Q: What is the difference between Claritron and other medicines that treat the same condition?

A: The medicine Claritron is a semi-synthetic derivative of a naturally occurring compound called Erythromycin. This modification is described in official documents as enhancing the drug's properties, resulting in improved acid stability and better absorption when taken by mouth.

Q: Has Claritron been studied in children?

A: Official documents state that the safety and effectiveness of Claritron have not been established for children younger than 6 months of age. For pediatric patients typically between 6 months and 12 years, the specific amount needed is calculated based on body weight, typically using the oral suspension form.

Q: Is there any research evidence showing Claritron helps with my symptoms?

A: Research evidence has explored the association between the compound and potential support for knee-joint function. Studies have specifically examined whether the compound is associated with a reduction in pain and stiffness metrics in participants with mild to moderate Osteoarthritis (OA).

Q: Can I use Claritron if I have kidney problems?

A: Official documentation notes that a dosage adjustment is typically required for adults who have severe renal impairment, which means a reduction in kidney function. The medicine is also listed as strictly contraindicated for patients who have severe liver failure combined with a reduction in kidney function.

Q: Do I need to take Claritron with food?

A: Whether Claritron must be taken with food depends on the specific form of the medicine. Immediate-release tablets and the liquid suspension may be taken with or without food. However, extended-release tablets are specified to be taken with food to ensure adequate absorption and must be swallowed whole.

Q: What are the official approved uses of Claritron?

A: Official regulatory labels state that Claritron is approved for treating various bacterial infections, including those affecting the respiratory tract and skin/soft tissues. It is also used in combination with other medicines to treat duodenal ulcers caused by the bacterium H. pylori.

Q: Can Claritron cause changes in mood or behavior?

A: Regulatory adverse event reporting indicates that psychiatric events are among the possible side effects associated with Claritron use. Specifically, events like nightmares are reported more commonly in adults.

Q: What age group is Claritron typically used for?

A: Claritron is typically prescribed to adults and to children who are 6 months of age and older. Official documents state that the modified-release tablet form is generally not for use in children under 12 years old.

Q: What are the known severe side effects listed for Claritron?

A: Official serious safety information includes a potential increased long-term risk of heart problems or death in patients with pre-existing heart disease. Regulatory documents also report rare cases of serious reactions such as Stevens-Johnson syndrome and liver function damage.

Q: How quickly does Claritron start working?

A: Regulatory pharmacokinetic data describes the elimination half-life of the active ingredient as approximately 3 to 4 hours, which relates to the time it takes for the medicine to be processed by the body. Official sources do not provide information on the subjective time required for symptoms to begin to resolve.

Q: Can Claritron cause me to feel tired or dizzy?

A: Official patient information indicates that the medicine may be associated with feelings of dizziness or drowsiness (tiredness). This information is provided in the context of warnings against driving or operating machinery if these effects are experienced.

Q: Are there any common foods or drinks to avoid while using Claritron?

A: Official regulatory data does not strictly prohibit the consumption of common foods or drinks. However, the Extended-Release form must be taken with food to ensure proper absorption. Additionally, a minor drug-food interaction is noted, and it is important that patients follow all instructions provided by their healthcare provider.

Q: Is Claritron a controlled substance or addictive?

A: Claritron is officially classified as a macrolide antibiotic and is available only by prescription. It is not designated as a controlled substance by regulatory bodies.

Q: What happens if I stop taking Claritron suddenly?

A: Official guidance emphasizes the importance of taking the medicine for the entire duration prescribed by a healthcare professional. Stopping the medicine early may increase the risk of a resistant infection developing.

Q: Does Claritron affect birth control pills?

A: Regulatory interaction data indicates that the medicine may affect the levels of oral contraceptives containing estrogen. This change in levels can potentially increase the risk of pregnancy or breakthrough bleeding.

Q: How long does the effect of Claritron last after I take it?

A: Regulatory pharmacokinetic data describes the elimination half-life of the active ingredient as approximately 3 to 4 hours. This value indicates how quickly the concentration of the medicine is reduced in the body.

Q: Does Claritron interact with herbal supplements?

A: Official regulatory and patient information sources advise consulting with a doctor or pharmacist about using herbal remedies, supplements, or vitamins while taking Claritron. This is to ensure there are no unintended interactions with the medicine.

Q: Is Claritron gluten-free or suitable for vegans?

A: Official excipient lists show that certain formulations, such as the prolonged-release tablets, contain lactose monohydrate. Patients with known intolerances to this ingredient should consult official labeling for their specific product form.

Q: Is it okay to drink coffee while using Claritron?

A: Regulatory data reports a minor interaction between the active ingredient in Claritron and caffeine. Patients should consult their healthcare professional for specific guidance.

Q: Does Claritron interact with pain relievers like ibuprofen?

A: Based on official drug interaction checks, no interaction has been identified between clarithromycin and the pain reliever ibuprofen.

Q: What should I do if I forget to take Claritron?

A: Official patient information outlines a common procedure for managing a forgotten dose. If a dose is forgotten, take it as soon as it is remembered, unless it is almost time for the next scheduled dose. It is noted that extra medicine should not be taken to make up for the missed dose.

Q: Is Claritron a new drug, or has it been around for a while?

A: The active ingredient in Claritron, Clarithromycin, has a long history, as it was developed in 1980 and approved for use in 1990. It is classified as a semi-synthetic derivative.

Q: Can Claritron affect my ability to drive or operate machinery?

A: Official patient information advises that if the medicine causes side effects like dizziness or drowsiness, patient information advises against driving or operating machinery. This is a common warning for medicines that may affect alertness.

Q: Is Claritron safe to use with multivitamins?

A: Official sources advise consulting with a doctor or pharmacist about the use of any vitamins or supplements, including multivitamins, while using this medicine. This ensures that the components of the supplement do not interfere with the medicine's action.

Q: What is the most frequently reported side effect of Claritron?

A: Regulatory adverse event reporting indicates that the most frequently reported side effect varies depending on the age of the patient. In adults, taste disorder (dysgeusia) is often reported as a common adverse event.

Q: Does Claritron affect blood sugar levels?

A: Regulatory drug interaction data notes that concurrent use of the medicine with insulin or other medications used to manage diabetes has occasionally resulted in reports of hypoglycemia (low blood sugar).

Q: Is Claritron available as a generic medicine?

A: The active ingredient in Claritron, Clarithromycin, is available as a generic medication.

Q: Is Claritron a high-risk medication?

A: The FDA has issued a Drug Safety Communication to inform the public about a specific safety concern regarding the medicine. This communication addresses a potential increased long-term risk of heart problems in patients with pre-existing heart disease.

Q: What is the role of Claritron in combination therapy?

A: Official prescribing information indicates that Claritron is used as part of a combination therapy. Specifically, it is used with other medicines to treat duodenal ulcers caused by the bacterium H. pylori.

Q: Does Claritron interact with alcohol, and if so, how is it described?

A: Official documents do not list a specific contraindication for the medicine and alcohol. However, general guidance regarding antibiotics suggests that combining them with alcohol may worsen common side effects such as stomach upset and dizziness.

Q: Can I use Claritron if I am lactose intolerant?

A: Official excipient lists show that certain formulations, such as the prolonged-release tablets, contain lactose monohydrate. Regulatory documents state that this form should not be used by patients with rare hereditary problems of galactose intolerance.

Q: Is Claritron approved in countries outside of the US?

A: Yes, the medicine is approved for use in multiple regions globally. Regulatory and patient information documents exist from bodies such as Health Canada, the European Medicines Agency (EMA), and the UK's MHRA.

Q: Why is the medicine sometimes referred to by a different name?

A: The medicine may be referred to by its brand name, Claritron, which is used for marketing. It is also referred to by its non-proprietary name, Clarithromycin, which is the name of the active chemical ingredient.

Q: Does Claritron require any special blood tests while using it?

A: Official documents indicate that Therapeutic Drug Monitoring (TDM) may be necessary in some patients. This specialized monitoring may be required for individuals with existing liver or kidney impairment or when very high doses of the medicine are used.

How should Claritron be stored and disposed of?

How to Store and Dispose of Claritron (Clarithromycin)

The official labeling outlines specific conditions required to maintain the stability and integrity of Claritron.

Storage and Handling

Claritron tablets and dry powder must be stored at controlled room temperature, generally defined as below 30 C, and protected from light and moisture. The medicine must always be kept out of the sight and reach of children.

  • Oral Suspension: The liquid suspension form must not be refrigerated after it is mixed, as this can cause thickening. The reconstituted suspension has a limited in-use stability and must be used or discarded within 14 days.

Disposal Instructions

Expired or unused Claritron should be discarded according to official regulatory guidelines. The preferred method is to use a drug take-back program or authorized collection site. If a take-back option is unavailable, the product should be mixed with an undesirable substance and sealed in a container before disposal in the household trash, following established regulatory procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Claritron found in:

A-Z Index: